Chinook Therapeutics, Inc.

KDNYNASDAQHealthcare

$40.39

+$0.09(+0.22%)

Market Cap$2.7B

P/E Ratio—

52W High$40.51

52W Low$18.34

Avg Volume2.0M

Open$40.31

Beta0.67

Overview

Chinook Therapeutics, Inc. (KDNY) Number of Employees – History & Annual Headcount

Annual SEC headcount, year-over-year change, and per-employee efficiency — chart and full history below.

SEC EDGAR · FMP · KDNY · as of Feb 27, 2023

Latest filing snapshot

214

+76+55.07%vs prior year

Chinook Therapeutics, Inc. (KDNY) employee data is sourced from the annual SEC 10-K filing. As of 2022, full-time employees only. Global consolidated headcount. View SEC filing ↗

SEC 10-K·Period end: 2022-12-31·Full-time · Global

Total Employees

214

Change (1Y)

+76

Growth % (1Y)

+55.07%

Revenue / Employee

$28.6K

Net Income / Employee

$-862.7K

Market Cap

$2.7B

KDNY Employee Count

2015 – 2022 · Annual · SEC filing

Source: SEC annual filings · Hover bar to view year data · Click to view original filing

Employees History

Filing Date	Period End	Employees	Change (1Y)	Growth (1Y)
2023-02-27	2022-12-31	214	+76	+55.07%
2022-03-17	2021-12-31	138	+33	+31.43%
2021-04-07	2020-12-31	105	+9	+9.38%
2020-03-09	2019-12-31	96	-56	-36.84%
2019-02-27	2018-12-31	152	-10	-6.17%
2018-03-01	2017-12-31	162	+4	+2.53%
2017-03-01	2016-12-31	158	+47	+42.34%
2016-03-08	2015-12-31	111	—	—

▸ Source: SEC Annual Reports (Form 10-K / 20-F). Employee counts as of fiscal year end. Click the ↗ icon at the end of a row to open the original SEC filing in a new tab.

Related Companies — Employee Count

Biotechnology

#SymbolCompanyEmployeesMkt Cap

Calliditas Therapeutics AB (publ)

222$2.1B #3

KDNY

Chinook Therapeutics, Inc.YOU

214$2.7B #4

FUSN

Fusion Pharmaceuticals Inc.

DICE Therapeutics, Inc.

71$2.3B #7

LBPH

Longboard Pharmaceuticals, Inc.

50$2.3B

Source: /stock-peers + /profile.fullTimeEmployees · Click row → /employees · Sorted by headcount · KDNY peer comparison

About KDNY employees

KDNY Employees · Headcount

Chinook Therapeutics, Inc. (KDNY) employee data is sourced from the annual SEC 10-K filing. As of 2022, Chinook Therapeutics, Inc. had 214 full-time employees globally. Full-time employees only. Global consolidated headcount.

Chinook Therapeutics, Inc. employs 214 full-time employees as of the latest filing within the Biotechnology industry. Revenue per employee stands at $28,636, reflecting the company's operational efficiency.

Chinook Therapeutics, Inc.'s workforce increased by 76 (55.07%) in 2022 compared to the prior fiscal year. The historical trend reflects the company's expansion and contraction cycles.

Chinook Therapeutics, Inc.'s revenue per employee of $28,636 positions it among the notable performers in the Biotechnology sector for operational efficiency.

Revenue Financial statements Net income SEC filings Price history Forecast & ratings Ownership Earnings

Frequently Asked Questions

KDNY Employees · 5 questions

As of the latest SEC 10-K filing (2022), Chinook Therapeutics, Inc. had 214 full-time employees globally. This figure is sourced from the company's mandatory annual disclosure to the SEC.

Chinook Therapeutics, Inc. employee counthow many employees does Chinook Therapeutics, Inc. haveKDNY total employees 2022

▸ Data source: FMP /historical-employee-count · SEC EDGAR annual filings · As reported · Global consolidated headcount · As of 2023-02-27